{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:59:55Z","timestamp":1790197195012,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00117-026-01646-y","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:59:29Z","timestamp":1785455969000},"page":"752-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bildgebung bei monoklonalen Plasmazellerkrankungen","Imaging in monoclonal plasma cell disorders"],"prefix":"10.1007","volume":"66","author":[{"given":"Jakob","family":"Neubauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"1646_CR1","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2022) Diagnostik, Therapie und Nachsorge f\u00fcr Patienten mit monoklonaler Gammopathie unklarer Signifikanz (MGUS) oder Multiplem Myelom. Langversion 1.0, 2022, AWMF-Registernummer 018\/035OL."},{"key":"1646_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar\u00a0SV, Dimopoulos\u00a0MA, Palumbo\u00a0A et\u00a0al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"1646_CR3","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass\u00a0J, Usmani\u00a0S, Rajkumar\u00a0SV et\u00a0al (2019) International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302\u2013e312","journal-title":"Lancet Oncol"},{"key":"1646_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos\u00a0MA, Terpos\u00a0E, Boccadoro\u00a0M et\u00a0al (2025) EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 22:680\u2013700","journal-title":"Nat Rev Clin Oncol"},{"key":"1646_CR5","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo\u00a0M, Terpos\u00a0E, Nanni\u00a0C et\u00a0al (2017) Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 18:e206\u2013e217","journal-title":"Lancet Oncol"},{"key":"1646_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou\u00a0C, Hillengass\u00a0J, Delorme\u00a0S et\u00a0al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291:5\u201313","journal-title":"Radiology"},{"key":"1646_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0124-1","volume":"8","author":"LA Moulopoulos","year":"2018","unstructured":"Moulopoulos\u00a0LA, Koutoulidis\u00a0V, Hillengass\u00a0J et\u00a0al (2018) Recommendations for acquisition, interpretation and reporting of whole-body low-dose CT in patients with multiple myeloma and other plasma cell disorders: IMWG Bone Working Group. Blood Cancer J 8:95","journal-title":"Blood Cancer J"},{"key":"1646_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni\u00a0E, Tacchetti\u00a0P, Cavo\u00a0M (2019) Imaging in multiple myeloma: How? When? Blood 133:644\u2013651","journal-title":"Blood"},{"key":"1646_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","volume":"52","author":"C Nanni","year":"2025","unstructured":"Nanni\u00a0C, Deroose\u00a0CM, Balogova\u00a0S et\u00a0al (2025) EANM guidelines on the use of 18F-FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. Eur J Nucl Med Mol Imaging 52:171\u2013192","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1646_CR10","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","volume":"117","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos\u00a0MA, Kyle\u00a0R, Fermand\u00a0JP et\u00a0al (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:4701\u20134705","journal-title":"Blood"},{"key":"1646_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos\u00a0MA, Moreau\u00a0P, Terpos\u00a0E et\u00a0al (2021) Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:309\u2013322","journal-title":"Ann Oncol"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"J Hillengass","year":"2010","unstructured":"Hillengass\u00a0J, Fechtner\u00a0K, Weber\u00a0MA et\u00a0al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J\u00a0Clin Oncol 28:1606\u20131610","journal-title":"J Clin Oncol"},{"key":"1646_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.78","volume":"7","author":"J Hillengass","year":"2017","unstructured":"Hillengass\u00a0J, Moulopoulos\u00a0LA, Delorme\u00a0S et\u00a0al (2017) Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J 7:e599","journal-title":"Blood Cancer J"},{"key":"1646_CR14","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos\u00a0E, Zamagni\u00a0E, Lentzsch\u00a0S et\u00a0al (2021) Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol 22:e119\u2013e130","journal-title":"Lancet Oncol"},{"key":"1646_CR15","doi-asserted-by":"crossref","unstructured":"Major\u00a0NM, Helms\u00a0CA, Richardson\u00a0WJ (2000) The \u201cmini brain\u201d: plasmacytoma in a vertebral body on MR imaging. AJR Am J Roentgenol 175:261\u2013263","DOI":"10.2214\/ajr.175.1.1750261"},{"key":"1646_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13509","volume":"171","author":"C Messiou","year":"2015","unstructured":"Messiou\u00a0C, Kaiser\u00a0M (2015) Whole body diffusion-weighted MRI: a\u00a0new view of myeloma. Br J Haematol 171:29\u201337","journal-title":"Br J Haematol"},{"key":"1646_CR17","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2021210048","volume":"3","author":"C Messiou","year":"2021","unstructured":"Messiou\u00a0C, Porta\u00a0N, Sharma\u00a0B et\u00a0al (2021) Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma. Radiol Imaging Cancer 3:e210048","journal-title":"Radiol Imaging Cancer"},{"key":"1646_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01327-4","volume":"15","author":"C Messiou","year":"2025","unstructured":"Messiou\u00a0C, Porta\u00a0N, Koh\u00a0DM et\u00a0al (2025) Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma. Blood Cancer J 15:122","journal-title":"Blood Cancer J"},{"key":"1646_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau\u00a0P, Attal\u00a0M, Caillot\u00a0D et\u00a0al (2017) Prospective evaluation of magnetic resonance imaging and 18F-FDG-PET\/CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J\u00a0Clin Oncol 35:2911\u20132918","journal-title":"J Clin Oncol"},{"key":"1646_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni\u00a0C, Versari\u00a0A, Chauvie\u00a0S et\u00a0al (2018) Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian Myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 45:712\u2013719","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1646_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche\u00a0L, Angtuaco\u00a0E, McDonald\u00a0JE et\u00a0al (2017) Low expression of hexokinase\u20112 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30\u201334","journal-title":"Blood"},{"key":"1646_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0549-1","volume":"11","author":"J Caers","year":"2018","unstructured":"Caers\u00a0J, Paiva\u00a0B, Zamagni\u00a0E et\u00a0al (2018) Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J\u00a0Hematol Oncol 11:10","journal-title":"J Hematol Oncol"},{"key":"1646_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar\u00a0S, Paiva\u00a0B, Anderson\u00a0KC et\u00a0al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"1646_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni\u00a0E, Nanni\u00a0C, Dozza\u00a0L et\u00a0al (2021) Standardization of 18F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J\u00a0Clin Oncol 39:116\u2013125","journal-title":"J Clin Oncol"},{"key":"1646_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi\u00a0NC, Avet-Loiseau\u00a0H, Rawstron\u00a0AC et\u00a0al (2017) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a\u00a0meta-analysis. JAMA Oncol 3:28\u201335","journal-title":"JAMA Oncol"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-026-01646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-026-01646-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-026-01646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:02:36Z","timestamp":1790193756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-026-01646-y"}},"subtitle":["Multiples Myelom, Smouldering multiple myeloma und MGUS","Multiple myeloma, smouldering multiple myeloma and MGUS"],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s00117-026-01646-y","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Neubauer gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}